Mather Group, Llc. Cue Biopharma, Inc. Transaction History
Mather Group, Llc.
- $8.58 Billion
- Q1 2025
A detailed history of Mather Group, Llc. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 1,000 shares of CUE stock, worth $740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$740% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CUE
# of Institutions
57Shares Held
11.5MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$3.7 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$1.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$559,9840.0% of portfolio
-
Geode Capital Management, LLC Boston, MA631KShares$467,1470.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$354,0900.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $26.2M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...